Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Prestige Brands Holdings — ICR Conference 2017
35 slides from Prestige Consumer Healthcare's conference presentation, Jan 10, 2017
Slide 1: ICR Conference 2017
ICR Conference 2017 January 10 th and 11 th Ron Lombardi, President & CEO | Christine Sacco, CFO NYSE: PBH Exhibit 99.1
Slide 2: Forward-looking statements
2 This presentation contains certain “forward - looking” statements within the meaning of the Private Securities Litigation Reform A ct of 1995, such as statements regarding the Company’s expected financial performance, including revenue growth, adjusted EPS, and adjusted fr ee cash flow; the Compan
Slide 3: Agenda for Today's Discussion
3 Agenda for Today’s Discussion I. Who Is Prestige Brands? II. Performance Highlights III. Fleet Overview IV. FY 17 Outlook and the Road Ahead
Slide 4: I. Who Is Prestige Brands?
|. Who Is Prestige Brands? a oe Od [steien MM BC 22222) (NE ows. §=— Debrox:
Slide 5: Largest independent OTC products company in North America
5 Prestige Brands is the largest independent OTC products Company in North America. The Company markets and sells well - known, brand name, over - the - counter healthcare and household cleaning products throughout the U.S. and Canada, Australia, and certain other international markets. We operate i
Slide 6: Helping Consumers Care for Themselves
6 Source: Company records Helping Consumers Care for Themselves
Slide 7: Prestige Brands Snapshot
7 $ * Market data as of January 5, 2017 ** Includes approximate run - rate revenue pro forma for the acquisition of DenTek and pending acquisition of Fleet Prestige Brands Snapshot 78% * +2.0x vs. S&P 500 78% (1) ~$1 Billion ** $4.3 Billion *
Slide 8: 3 Key Drivers of Long-Term Shareholder Value
8 ~ 85 % of portfolio now positioned for durable, consistent organic growth Best - in - class ongoing FCF generation $190M+ (6) of adjusted FCF expected for FY17 Completed 4 acquisitions since 2013 Investor Day , plus Fleet acquisition announcement 3 Key Drivers of Long - Term Shareholder Va
Slide 9: Repeatable and Disciplined Approach to M&A
9 Repeatable and Consistently Disciplined Approach to M&A Eight Acquisitions in Past Six Years Platform Expansion Geographic Expansion 2010 2012 2013 2014 2011 April 2014 July 2013 April 2014 December 2011 December 2010 September 2010 November 2015 2015 North American Brands 2016 December 2016
Slide 10: Diversified Portfolio of Leading, Trusted Brands
10 27% 12% 12% 12% 11% 16% 11% Diversified Portfolio of Leading, Trusted Brands Women’s Health Cough/ Cold Analgesics Eye & Ear Care GI Skin Care Oral Care Source : OTC revenues for FY 16 Note: Pro forma for DenTek acquisition and pending Fleet acquisition; excludes Household
Slide 11: Company Brands Average Over $100MM at Retail
11 Company Brands Firmly Average Over $100MM at Retail FY 10 FY 13 Today (Pro Forma for Fleet) +2.1x +1.6x Source: IRI MULO+C - Store (Retail Dollar Sales).
Slide 12: II. Performance Highlights
12 II. Performance Highlights
Slide 13: Strong Financial Performance in First Half FY17
13 Strong Financial Performance in First Half FY 17 Revenue of $424.6 million , up 6.6% versus 1H FY 16 (FY 17 Outlook +4.5% to 6.0%) Adjusted EPS of $1.22 (2 ) , up 8.9% versus 1H FY 16 (FY 17 Outlook +6% to +9% ($2.30 to $2.36) ( 5) Adjusted Free Cash Flow of $99.6 million (2) , up 12.0% versus 1H
Slide 14: Consistent Consumption Growth for Invest for Growth Portfolio
14 Continued Strong and Consistent Consumption Growth for Invest for Growth Portfolio Source: Data reflects retail dollar sales percentage growth versus prior period for consumption growth and organic revenue growth. FY 15 and FY 16 data shown as previously presented for Core OTC. Q1 and Q2 FY 17 da
Slide 15: III. Fleet Overview
lll. Fleet Overview a oe Od Person gM BC 2222) (NE ows. §=— Debrox:
Slide 16: Transaction Overview
16 Transaction Overview ▪ On December 21 st Prestige Brands announced an agreement to acquire C.B. Fleet Company, Inc. for $825 million – Fleet has Revenue of approximately $205 * million – Purchase price represents ~11x Pro Forma Adjusted EBITDA, including expected synergies – Expected to be immedi
Slide 17: Fleet Overview
17 Fleet Overview Infant Care Feminine Care Gastrointestinal Care #1 #1 #1 Source: IRI MULO L52 week period ending 11/27/16. A Leading Consumer Healthcare Company with Strong Heritage #4 ▪ Founded in 1869 and based in Lynchburg, VA ▪ Leading, privately - held Consumer Healthcare Company that manufac
Slide 18: A Focused, High Performing Portfolio
18 2013A 2014A 2015A 2016 Sept. LTM 16.8% Feminine Care Gastrointestinal Care Infant Care Attractive Net Revenue Growth Focused Category Presence Note: Pie chart refers to approximate Fleet Revenue mix by category as of LTM ending September, 2016 High Single Digits CAGR A Focused, High Performing Po
Slide 19: Summer's Eve Leads Feminine Care
19 2.3% 0.8% 0.9% 4.9% Fastest Growing * Feminine Hygiene Largest Segment * Summer’s Eve® is the Market Leader in Largest and Fastest Growing Segment of Feminine Care 39% 34% 27% Feminine Hygiene Vaginal Treatments Intimacy Enhancements Total Feminine Care: ~$850 million 5 - Yr CAGR Intimacy Enhance
Slide 20: Fleet Portfolio Aligned with Focus OTC Categories
20 Fleet Portfolio Well Aligned with Focus OTC Categories for Prestige Positioning Over 140 Years of Fast, Gentle, & Effective Relief Serious Relief for Serious Gas & Heartburn Keeping Kids Regular Let’s Kick Some Rash Year Launched 1953 1970 (Acquired 2012) 2008 1978 (Acquired in 2011) Key Categori
Slide 21: Leverage World Class Manufacturing Platform
21 Opportunity to Leverage World Class Manufacturing Platform Wholly - owned 310,000 square foot facility in Lynchburg , VA on 14.9 acres Efficient and scalable manufacturing capabilities include blow molding, processing, filling and packaging ~ 65% of sales are manufactured in - house Stron
Slide 22: IV. The Road Ahead
IV. The Road Ahead a oe Od Person gM BC 2222) (NE ows. §=— Debrox:
Slide 23: Key Drivers of Long-Term Shareholder Value
23 3 Key Drivers of Long - Term Shareholder Value Deliver Industry - Leading and Consistent Free Cash Flow Strategic and Disciplined M&A Strategy Grow Our Invest for Growth Portfolio Portfolio of recognizable brands in attractive consumer health industry Established expertise in brand - building
Slide 24: Achieve Invest for Growth Target
24 Achieve “Invest for Growth” Target Greater Proportion of #1 / #2 Brands Meaningfully Enhanced Scale Improved Key Category Exposure (Pro Forma) ~$800 ~$1,000 Standalone Pro Forma ~80% ~85% Standalone Pro Forma ~70% ~75% Standalone Pro Forma Women’s Health Gastrointestinal Analgesics Cough/Cold Eye
Slide 25: Industry Leading Free Cash Flow Provides Rapid Deleveraging
25 Industry Leading Free Cash Flow Provides Rapid Deleveraging $59 $ 86 $67 $ 127 $ 130 $ 164 $ 183 $185 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17E $190 (6) Adjusted Free Cash Flow in Millions (2) Superior EBITDA margin profile Largely outsourced manufacturing with minimal capital outlays Discip
Slide 26: Historical and Estimated Leverage Ratio
26 Industry Leading Free Cash Flow Provides Rapid Deleveraging 3.2x 3.5x 5.3x 5.0x 4.3x 4.3x 5.8x 5.2x 5.0x ~5.8x ~5.0x FY 10 FY 11 Q2 FY 11 FY 12 FY 13 FY 14 Q2 FY 15 FY 15 FY 16 FY 17E FY 18E North American Brands * Pro Forma Leverage ratio reflects net debt / covenant defined EBITDA Historical an
Slide 27: Prestige's Value Proposition
27 Prestige’s Value Proposition Diversified Portfolio of Leading, Trusted Brands 1 Leading Branded Competitor Across Key Categories 2 Established Organic Growth Playbook 3 Scalable and Efficient Platform 4 Organic Growth Reinforced by M&A 5 Superior Shareholder Value Creation + + + +
Slide 28: Bes aa ye Wo te er RG Ce IN Cs
Bes aa ye Wo te er RG Ce IN Cs Bo yo eb Dem ar EE Ce CS mm f= wf
Slide 29: Appendix
29 Appendix (1) Organic Revenue Growth on a constant currency basis is a Non - GAAP financial measure and is reconciled to its most closely related GAAP financial measure in our earnings release in the “About Non - GAAP Financial Measures ” section . (2) Adjusted G&A, Adjusted EBITDA, Adjusted EBITD
Slide 30: Reconciliation Schedules
30 Reconciliation Schedules Three Months Ended Sept. 30, Six Months Ended Sept. 30, 2016 2015 2016 2015 (In Thousands) GAAP Total Revenues $ 215,052 $ 206,065 $ 424,627 $ 398,197 Adjustments: DenTek revenues (17,214) - (33,841) - Revenues associated with divested brands - (6,922) - (6,922) Total adj
Slide 31: Adjusted G&A Reconciliation Schedules
31 Adjusted G&A Reconciliation Schedules Cont’d Three Months Ended Sept. 30, Six Months Ended Sept. 30, 2016 2015 2016 2015 (In Thousands) GAAP General and Administrative Expense $ 18,795 $ 16,462 $ 38,252 $ 34,051 Adjustments: Costs Associated with CEO transition - - - 1,406 Legal and professional
Slide 32: Adjusted EBITDA Reconciliation
32 Reconciliation Schedules Cont’d Adjusted EBITDA Three Months Ended Sept. 30, Six Months Ended Sept. 30, 2016 2015 2016 2015 (In Thousands) GAAP Net (Loss) Income $ 32,195 $ 31,803 $ 26,664 $ 57,976 Interest expense, net 20,830 20,667 41,957 42,551 (Benefit) provision for income taxes 18,033 17,42
Slide 33: Adjusted Net Income and Adjusted EPS Reconciliation
33 Adjusted Net Income and Adjusted EPS Reconciliation Schedules Cont’d Three Months Ended Sept. 30, Six Months Ended Sept. 30, 2016 2015 2016 2015 Net Income EPS Net Income EPS Net Income EPS Net Income EPS (In Thousands) GAAP Net Income $ 32,195 $ 0.60 $ 31,803 $ 0.60 $ 26,664 $ 0.50 $ 57,976 $ 1.
Slide 34: Adjusted Free Cash Flow Reconciliation
34 Reconciliation Schedules Cont’d Adjusted Free Cash Flow Three Months Ended Sept. 30, Six Months Ended Sept. 30, 2016 2015 2016 2015 (In Thousands) GAAP Net (Loss) Income $ 32,195 $ 31,803 $ 26,664 $ 57,976 Adjustments: Adjustments to reconcile net (loss) income to net cash provided by operating a
Slide 35: Projected EPS and Projected Free Cash Flow
35 Reconciliation Schedules Cont’d Projected EPS Projected Free Cash Flow 2017 Projected EPS Low High Projected FY'17 GAAP EPS $ 1.55 $ 1.61 Adjustments: Costs associated with DenTek integration 0.08 0.08 Loss on sale of assets 0.67 0.67 Total Adjustments 0.75 0.75 Projected Non - GAAP Adjusted EPS